In September, Click Therapeutics announced successful results from its phase 3 trial testing the use of a digital therapeutic CT-132 for treating adults’ migraines. The therapy is designed to be used alongside a 12-week regimen of clinical intervention intended to reduce brain hypersensitivity by modulating responses to environmental and internal stimuli. Results were gathered from the randomized ReMMi-D trial.

Top read nonopioid pain management stories from the year 2024 | image credit: volha_r / stock.adobe.com

Nonopioid Suzetrigine Demonstrates Positive Phase 3 Results for Acute Pain

At the annual meeting of the American Society of Anesthesiologists, which took place from October 18 to 22 in Philadelphia, Pennsylvania, researchers presented positive phase 3 clinical trial results for suzetrigine—a nonopioid pain medication used for acute pain management. Known as a “potent and highly selective inhibitor of Na_V1.8,” suzetrigine is also considered to have zero potential for misuse or abuse.

Despite Benefits, Mediterranean Diet Adherence in RA Remains Low | ACR Convergence

In a research study presented at ACR Convergence 2024, researchers found that patients with rheumatoid arthritis (RA) who were willing to participate in dieting education were still nonadherent to Mediterranean dietary patterns. The cost and accessibility of healthy and dietary-proven foods hindered patients’ ability to reap the benefits of a diet like the Mediterranean. Food cost and access should be addressed before patients’ nonadherence.

Examining Barriers to Assessing and Treating Pain in Pediatric Patients

Issues surrounding the various types of pain have continuously persisted, whether discussing acute, episodic, or chronic pain. While extensive research regarding adults’ outcomes in the area of pain exists, the same is not quite true for pediatric patients. Madison Irwin, PharmD, BCPS, a clinical pharmacist specialist in palliative care at University of Michigan Health and a clinical assistant professor at the University of Michigan College of Pharmacy, sat down with Drug Topics to discuss the challenges and trends regarding the treatment of pediatric pain.

Navigating Nephrolithiasis: A Pharmacist's Perspective

At the PAINWeek National Conference, held September 3 to 6 in Las Vegas, Nevada, Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, professor at WVU School of Pharmacy, gave a presentation about his experience with nephrolithiasis—the condition that creates kidney stones. In his presentation, Garofoli said “never again” to kidney stone pain, providing conference attendees with the tools and resources to also help patients with their nephrolithiasis-related pain.

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.